PIERIS PHARMACEUTICALS, INC. (NASDAQ:PIRS) Files An 8-K Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain OfficersItem 5.02: Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.
(d)
On April 24, 2018, the Board of Directors (the “Board”) of Pieris Pharmaceuticals, Inc. (the “Company”), following the recommendation of the Nominating and Corporate Governance Committee of the Board, elected Ann Barbier, M.D., to the Board to serve as a ClassII Director with a term expiring at the Company’s 2019 annual meeting of stockholders. Dr. Barbier is currently the Chief Medical Officer of Translate Bio. Prior to joining Translate Bio, Dr. Barbier was Vice President of Clinical Development, Rare Genetic Diseases, at Agios Pharmaceuticals, where she led the development program of a small molecule in rare benign hematological diseases. Previously, Dr. Barbier spent seven years at Shire, most recently as Global Clinical Development Lead and Senior Medical Director, where she worked on a variety of rare genetic diseases including lysosomal storage diseases and hereditary angioedema. Her prior experience includes positions at Envivo, Johnson & Johnson and Aventis. During her career, Dr. Barbier has made significant contributions to several approved products such as Elaprase® (Hunter syndrome), Aubagio® (multiple sclerosis) and Firazyr® (hereditary angioedema) and has led several investigational new drug applications for new chemical entities. Additionally, she has authored more than 50 peer-reviewed scientific articles, book chapters and invited reviews. Dr. Barbier received her M.D. and Ph.D. in pharmacology from the University of Gent, Belgium, and a Master of Science from the Free University of Brussels, Belgium. She pursued a postdoctoral fellowship at the University of Tennessee in Memphis.
In connection with Dr.Barbier's election to the Board, and to the Company’sNon-EmployeeDirector Compensation Policy (the “Director Compensation Policy”), the Board granted to Dr. Barbier anon-statutorystock option to purchase up to 30,000 shares of the Company’s common stock. The stock option will have an exercise price per share equal to the closing price of the Company’s common stock on The Nasdaq Capital Market on April 25, 2018. The stock option will vest in equal quarterly installments at the end of each successive fiscal quarter following the date of grant, subject to Dr. Barbier's continued service as a director.
In addition, Dr. Barbier is entitled to receive an annual cash retainer of $35,000 for her service as anon-employeedirector of the Company to the Director Compensation Policy. Also in connection with Dr. Barbier's election to the Board, Dr. Barbier and the Company will enter into an indemnification agreement in the form the Company has entered into with certain of its othernon-employeedirectors, which form is filed as Exhibit 10.10 to the Company’s Current Report on Form8-K(FileNo.333-190728)filed by the Company on December18, 2014. Under this agreement, the Company will agree, among other things, to indemnify Dr. Barbier for certain expenses, including attorneys’ fees, judgments, fines and settlement amounts incurred by her in any action or proceeding arising out of her service as one of the Company’s directors.
There are no arrangements or understandings between Dr. Barbier and any other person to which Dr. Barbier was appointed as a director. There are no transactions to which the Company is a party and in which Dr. Barbier has a material interest that is required to be disclosed under Item404(a) of RegulationS-K. Dr. Barbier has not previously held any positions with the Company and has no family relations with any directors or executive officers of the Company.
Item 5.02 Financial Statements and Exhibits
(d)Exhibits.
PIERIS PHARMACEUTICALS, INC. ExhibitEX-99.1 2 a180424pirspressreleasea.htm EXHIBIT 99.1 a180424pirspressreleasea
Pieris Pharmaceuticals Appoints Ann Barbier,…To view the full exhibit click here
About PIERIS PHARMACEUTICALS, INC. (NASDAQ:PIRS)
Pieris Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company. The Company’s pipeline includes immuno-oncology multi-specifics tailored for the tumor micro-environment, an inhaled Anticalin to treat uncontrolled asthma and a half-life-optimized Anticalin to treat anemia. Its Anticalins proteins are a class of low molecular-weight therapeutic proteins derived from lipocalins, which are naturally occurring low-molecular weight human proteins typically found in blood plasma and other bodily fluids. It is focused on developing three drug candidates, which include PRS-080, PRS-060 and PRS-300 series. Its PRS-080 is an Anticalin drug candidate targeting hepcidin. The Company’s second Anticalin drug candidate, PRS-060, binds to the IL-4 receptor alpha-chain (IL-4RA), thereby inhibiting the actions of IL-4 and IL-13, two cytokines known to be mediators in the inflammatory cascade that causes asthma and other inflammatory diseases. PRS-343 is an Anticalin-based drug candidate.